Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ: VNDA )

4.710 -0.140 (-2.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 435,646
Open 4.770
Bid (Size) 4.660 (1)
Ask (Size) 4.800 (20)
Prev. Close 4.850
Today's Range 4.660 - 4.830
52wk Range 3.710 - 6.750
Shares Outstanding 55,638,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga

Performance

YTD
-2.28%
-2.28%
1 Month
+1.95%
+1.95%
3 Month
-2.28%
-2.28%
6 Month
-6.18%
-6.18%
1 Year
+17.60%
+17.60%

More News

Read More
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts
Via Benzinga
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
Via Benzinga
Exposures Product Safety
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
Via Benzinga
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
Via The Motley Fool
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
Via Benzinga
Exposures Product Safety
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Via PressReach
Exposures Product Safety
What's Going On With Vanda Pharmaceuticals Shares Today?
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
Via Benzinga
Topics Stocks
Exposures US Equities
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
VNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
From Shareholder Capital LLC
Via GlobeNewswire
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.